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ABSTRACT   
Objectives –To assess the feasibility of conducting a glaucoma screening randomised controlled trial.  
Methods- Decision model based economic evaluation and value of information analysis. Model 
derived from a previous health technology assessment. Model updated in terms of structure and 
parameter estimates with data from surveys, interviews with the UK public and health care providers 
and routine sources.   
Results- On average, across varying ages of initiating screening (age 40-60), varying glaucoma 
prevalence (1-5%), varying screening uptake (30-100%) and the performance of current case finding, 
screening was not cost-effective at a £30,000 threshold per QALY from the perspective of the UK 
National Health Service (NHS).  The societal value of removing all uncertainty around glaucoma 
screening is £107 million at a threshold of £20,000 per Quality Adjusted Life Year (QALY).  For 
informing policy decisions on glaucoma screening, reducing uncertainty surrounding the NHS and 
personal social care cost of sight impairment (£74 million) was of most value, followed by reducing 
uncertainty in test performance (£14 million) and uptake of either screening or current eye care (£8 
million each).  
Conclusions- A glaucoma screening trial in the UK is unlikely to be the best use of research 
resources.  Further research to quantify the costs of sight impairment falling on the NHS and Personal 
Social services is a priority. Further development of glaucoma tests and research into strategies to 
promote uptake of screening or current eye care (e.g. through the use of a behavioural intervention) 
would be worthwhile.  
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INTRODUCTION 
Glaucoma, a chronic eye condition, is a leading cause of avoidable blindness in the UK and globally.  
1, 2 Open angle glaucoma is the commonest form. 3 Sight loss from glaucoma should be avoidable as 
early treatment of early glaucoma reduces the risk of sight loss, 4 yet in the UK around 3000 people 
are newly registered with sight impairment due to glaucoma per year. 5 Delayed detection and thus 
access to early treatment is the main risk factor for sight loss 6,7 and may be linked to areal or 
individual socio-economic deprivation. 8-10 Delayed access to treatment may occur at any stage of the 
referral pathway. There may be patient delay in terms of attendance for testing, process delay in terms 
of missed detection, or system delay leading to delayed referral for treatment. 11-13 The public health 
importance of glaucoma could indicate that a screening programme might be warranted. Before a 
screening policy is adopted evidence is required that the benefits of screening, namely reduced visual 
impairment, outweigh any harms, for example anxiety and cost.  
A prior economic modelling evaluation, found that screening the UK population, selected on age 
alone, for glaucoma was unlikely to be cost-effective as the prevalence is too low in all age groups 
(screening at age 40 or 65 or 75) modelled.5,14 A ‘surveillance’ programme targeted to higher risk 
groups (a sibling with glaucoma; ethnic minority groups; diabetics; or people with ocular risk factors 
such as raised intraocular pressure (IOP) and myopia) or those who do not normally access eye care 
might be worthwhile. The modelling evaluation, hereafter referred to as the glaucoma screening 
model, used the best data available but had acknowledged uncertainties in a number of areas e.g. how 
best to screen (tests and location), likely uptake of any screening programme and the effectiveness 
and coverage of current eye care services.  
The most robust way to evaluate any proposed screening programme is a randomised controlled trial 
(RCT). 15 There are no RCTs evaluating glaucoma screening. 16 Any future trial is likely to be large 
scale and thus costly. In a recent trial platform study, 17 we undertook a multi-component mixed-
methods approach to provide an evidence base to inform the optimal design for any future trial of 
glaucoma screening. We followed the Medical Research Council guidance for the development and 
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evaluation of complex interventions. 18 Our platform study consisted of two initial phases addressing 
specific issues– development of the screening test schedule and factors associated with motivation of 
the public to attend for screening. We took a systematic, theory-based approach to intervention 
development (identifying the evidence base, modelling process and developing outcomes) and 
explored the feasibility (for service providers), acceptability (for providers and users) and cost-
effectiveness (for health and social services) of trial components. These individual components are 
published elsewhere. 19-21 In this paper we report the integration of their findings (revised screening 
test schedule, likely uptake of screening and uptake of usual care) into the glaucoma screening 
economic model to inform whether a glaucoma screening trial is feasible.   
METHODS     
We used a Markov model to assess feasibility of a future glaucoma screening trial.  We took the 
perspective that interventions compared within the model could be delivered (technical feasibility) 
and were acceptable (likely uptake by providers and the public) in the context of the UK National 
Health Service.  Feasibility was judged in terms of likely value for money. 
We revised the structure of the existing glaucoma screening model5, 14 with the most likely cost-
effective glaucoma testing schedules that might be brought to trial based on the prior Delphi survey19 
and views of UK National Health Service (NHS) providers. 20 We updated parameter estimates for 
screening attendance based on our theory based survey of the public to identify factors associated with 
intention (motivation) to attend a hypothetical eye health test. We also used data collected within the 
survey on attendance by the public for an eye test within the last three years to estimate uptake of the 
comparator pathway within the model of opportunistic case finding within current UK eye care.  21 
Costs were reported in 2010 prices.  We sought estimates of attendance at current eye care services 
for the risk groups (age over 50, black ethnicity, diabetes, myopia, family history of glaucoma and 
low socioeconomic status (SES) from the British Household Panel Survey data (BHPS)  22 to develop 
and fit the probability distributions around the mean uptake of current eye care for the general 
population and subgroups using the Excel© add-on Oracle© Crystal Ball. Revised utility data were 
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based on the EQ-5D-3 L23 responses from 640 participants with ocular hypertension and glaucoma 
sampled from a secondary glaucoma service in the UK, Prior and colleagues submitted for publication 
2013. All other parameters were as detailed in the original glaucoma-screening model. 5, 14 The model 
allowed movement between health states every year, estimated costs from  a UK National Health 
Service (NHS) and a personal social services perspective and used the EQ-5D-3L quality of life 
weights to calculate Quality Adjusted Life Years (QALYS).  
The base case analysis conducted from NHS perspective, considered a cohort of 40-year old males 
with prevalence from 1% to 5%. Gender-specific variables were not available for any of the model 
parameters except for mortality. We used male mortality rates in the base-case analysis, consistent 
with good modeling practice, as they are a conservative assumption for screening. Alternative 
likelihoods of attending screening  (e.g. 30% to 100%) and estimated costs and QALYs over their 
estimated lifetime with screening occurring every ten years were included. All costs and QALYs were 
discounted at 3.5%. The results are presented as incremental cost effectiveness ratios (ICERs).  
We conducted sensitivity analyses to identify plausible situations where screening might be 
considered worthwhile by varying screening start age and accuracy of glaucoma detection within 
current eye care services.  We used alternative data for uptake of current eye care (based on the survey 
of the public17 and BHPS data) for the whole population, for cohorts aged 50 and 60 as well as for 
higher risk subgroups of the adult population: those self-reported as having diabetes, sight problems in 
the family (excluding using spectacles) as a proxy for family history of glaucoma, and those at low 
household income (below £10,000 a year).  Data were not available within the BHPS to investigate 
the impact of ethnicity or myopia on the uptake rates of current eye care by these groupings.   
The effect of including Personal Social Services costs was explored in the sensitivity analysis by 
incorporating an annual cost of sight impairment varied between £1000 and £40,000.  The upper value 
is in line with Personal Social Services expenditure per person with sight impairment for England for 
2009-10. 24 Variations in cost of sight impairment were combined with variation in both prevalence 
rates and screening uptake to identify situations where screening might be worthwhile. We explored 
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the impact of increasing screening uptake because of a behavioural intervention and incorporating an 
additional cost for its provision. Without a behavioural intervention, glaucoma screening uptake was 
considered to be about 23% (based on our survey where 45% of the sample had strong intention 
scores (i.e. mean intention score of 7 on a 1-7 scale) 21 and the health behaviour literature that 50% of 
strong intenders will perform the intended behaviour. 25 We varied screening uptake from 30-100% to 
explore the impact of a behavioural intervention.  Reflecting a simple behavioural intervention such as 
an invitation letter targeted to improve motivation by making it easier to attend a screening 
appointment to a fully tailored intervention, and thus more costly, to persuade those with low 
intentions to attend.  The mean QALYs were expressed in UK pounds sterling by multiplying them by 
the willingness to pay for a QALY threshold (e.g. £30,000, see Figure 1). 
We also explored whether improved uptake of current eye care (ie enhanced current eye care) would 
be better than enrolling in a screening programme by modifying the model structure in order to 
compare two current practice strategies. Two uptake rates of current eye care were compared using 
BHPS data: 6.5% (corresponding to the uptake rate of low income groups) and 17% (estimated uptake 
of eye care for people with diabetes).  
All analyses incorporated probabilistic sensitivity analyses where the statistical imprecision is allowed 
for by sampling (e.g. 1000 times) from probability distributions attached to model mean parameter 
values.  The uncertainty in the model parameter values has cost implications as the ‘correct’ strategy 
might not be chosen.  In effect, if the analysis is run with alternative parameter values the choice of 
strategy might differ from the strategy finally adopted.  The sum of the benefits forgone for not being 
able to make the right decision due to this uncertainty is the Expected Value of Perfect Information 
(EVPI), as perfect information would eliminate the possibility of making wrong decisions. 26 The 
EVPI can be compared with the cost of reducing uncertainty in the model by collecting further 
information. The Expected Value of Parameter Perfect Information (EVPPI) is a similar concept but 
corresponds to a particular parameter or group of parameters in the model.  EVPPI was calculated to 
identify model parameters that contribute the most to the overall model decision uncertainty.  26 The 
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total EVPI and EVPPI were obtained by multiplying the EVPI and EVPPI estimated at an individual 
level by the number of individuals who would benefit from the intervention in a given period of time. 
We assumed 380,000 individuals with undiagnosed glaucoma in the UK, and an annual incidence of 
11,000 new cases,  5 a time horizon of 10 years (representing the lifespan of the technology; in this 
case a specific screening strategy) and a discount rate of 3.5%. 
RESULTS 
The revised model, now named the Glaucoma screening Platform Study [GPS] model, considers four 
possible screening strategies against a current practice comparator (no screening). The pathways 
modeled are specified in Box 1.  
Box 1   Description of the pathways compared within the Economic Model  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glaucoma	  screening	  Platform	  Study	  (GPS)1	   [Tonometry	   (measurement	   of	   intraocular	  pressure	  (IOP))	   and	   optic	   nerve	   photography	   (ONP)]:	   	   The	   population	   to	   be	   screened	   are	   invited	   to	   a	  primary	  care	  setting	  to	  undergo	  tonometry	  and	  ONP	  by	  a	  technician	  or	  nurse	  who	  has	  received	  some	  training.	  	  Screen	  positives	  referred	  to	  hospital	  eye	  service.	  
GPS11	  [IOP	  and	  visual	  field	  (VF)]:	  As	  above	  but	   screening	  with	   tonometry	  and	  visual	   field	   test	  (perimetry).	  Screen	  positives	  referred	  to	  hospital	  eye	  service.	  
GPS1d	   [IOP	   +	   ONP]:	   Screening	   with	   tonometry	   and	   optic	   nerve	   photography	   and	   screen	  positives	  examined	  by	  a	  specialised	  optometrist	  (diagnosis).	  Diagnostic	   test	  positives	  referred	  to	  hospital	  eye	  service	  
GPS11d	   [IOP	   +	   VF]:	   Screening	   with	   tonometry	   and	   visual	   field	   test	   (perimetry)	   with	   further	  diagnostic	  refinement	  and	  screen	  positives	  examined	  by	  a	  specialised	  optometrist	  (diagnosis).	  Diagnostic	  test	  positives	  referred	  to	  hospital	  eye	  service.	  
Current	   practice	   (UK	  NHS	   eye	   care):	   Opportunistic	   sight	   test	   at	   community	   optometrist	   with	  referral	  of	  suspect	  glaucoma	  to	  the	  hospital	  eye	  service.	  	  
IOP	   	  ≥26mmHg	   =	   screen	   positive;	   IOP	   <26mmHg	   +	   second	   technology	   test	   positive	   =	   screen	  positive;	  IOP	  <26	  mmHg+	  second	  technology	  test	  negative	  =	  return	  to	  current	  eye	  care	  and	  re-­‐screen	  cycle	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The screening test schedule, based on the views of service providers in terms of practicality and 
equity, was screening an inception cohort age 40. The screening strategies allow for a technician as 
first screening contact.  However, they differ in the tests performed. Glaucoma tests were either optic 
nerve photography (ONP) or screening mode perimetry (a measure of visual field [VF] sensitivity) 
with or without tonometry (a measure of intraocular pressure [IOP]). For those testing positive two 
pathways were explored, a diagnostic refinement step, using a specialised optometrist to examine 
screen positives as in the original model, or no referral refinement with screen test positives referred 
to a hospital based glaucoma service. 20 
 
Tables 1-2 show the updated data used in the GPS model. All other data in the model remained as for 
original model. 5, 14 
Table 1: Prevalence, incidence and progression of glaucoma 
Probability Value Source 
Prevalence of glaucoma 1% to 5% Assumption based on prevalence rates for general 
population and high prevalence sub-groups 5,14  
Progression to moderately severe glaucoma**  0.129 Progression data from GSM* 2007 5,14   
Progression to severe glaucoma  0.048 Progression data from GSM 2007 5,14 
Progression to visual impaired 0.042 Progression data from GSM 2007 5,14 
Annual probability of having an eye test in 
current practice (not screening): 
    
General population (adults over 40 years old) 0.1728 Based on survey of the UK public 21 
General population (adults over 40 years old) 0.0741 Based on BHPS data and alternative          
assumptions22 
Individuals with diabetes 0.1693 Based on BHPS data22 
Individuals with eye problems 0.1192 Based on BHPS data22 
Individuals within low income households 0.0653 Based on BHPS data 22 
   
*GSM: Glaucoma Screening Model. BHPS: British Household Panel Survey 
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**Visual Field Based Glaucoma staging5 Mean Defect Score, decibels (dB) 
Mild glaucoma -0·01 to -6·00dB  
Moderate glaucoma -6·01 to -12·00 dB 
Severe glaucoma -12·01 to -20·00 dB 
Visual impairment (partial sight/blind) -20·01dB or worse 
 
Table 2: Data on screening tests and test performance 
 
Probability Value Source 
Current eye care  
Optometry testing, sensitivity 0.32 GSM* 20075 
Optometry testing, specificity 0.99 GSM 20075 
Proportion of normal (no 
glaucoma) with IOP <26mmHg 0.96 GSM 20075 
Proportion of glaucoma with IOP 
≥26mmHg 0.35 GSM 20075 
Screening tests     
Optic nerve photography, 
sensitivity 0.73 GSM 20075 
Optic nerve photography, 
specificity 0.89 GSM 20075 
Perimetry (Frequency Doubling 
Technology-C-20-1), sensitivity 0.79 GSM 20075 
Perimetry (Frequency Doubling 
Technology -C-20-1) specificity 0.94 GSM 20075 
GSM: Glaucoma Screening Model 
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Base case analysis (inception cohort aged 40 estimated 1% glaucoma prevalence, screening every 
ten years and taking a NHS perspective) 
On average, screening the general population selected on age alone was not cost-effective at a 
£30,000 threshold (Table 3). It should be noted that as this is a population screening model we would 
expect a relatively small proportion of individuals to be identified with glaucoma and hence, on 
average for the population, only small gains in benefits.  
 
Table 3: Cost-effectiveness Base Case Analysis* results 
Screening 
acceptance 
(%) Strategy Cost QALYs** ICER*** 
 Current Practice £176 19.2530  
30% GPS11d (IOP + VF) £239 19.2537 88,908 
 GPS1d (IOP + ONP) £239 19.2536 (Dominated) 
 GPS II (IOP + VF) £266 19.2540 97,136 
 GPS I (IOP + ONP) £276 19.2539 (Dominated) 
 Current Practice £176 19.2530  
50% GPS11d (IOP + VF) £261 19.2539 74,408 
 GPS1d (IOP + ONP) £261 19.2538 (Dominated) 
 GPS II (IOP + VF) £304 19.2543 103,985 
 GPS I (IOP + ONP) £321 19.2541 (Dominated) 
 Current Practice £176 19.2530  
70% GPS11d (IOP + VF) £282 19.2541 68,718 
 GPS1d (IOP + ONP) £283 19.2540 (Dominated) 
 GPS II (IOP + VF) £342 19.2545 111,427 
 GPS I (IOP + ONP) £366 19.2544 (Dominated) 
*40 year-old inception cohort, 17% uptake of current practice, 1% glaucoma prevalence, lifetime time horizon. 
NHS costs. **QALY- quality adjusted life years. ***ICER = Incremental Cost Effectiveness Ratio.  ICERs are 
related to the, on average, cheapest non-dominated strategy.   
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Sensitivity analysis 
Screening start age and performance of current eye care-For cohorts starting at 50 and 60 years old, 
ICERs were, regardless of the level of screening uptake, well above the typically accepted threshold 
value of £30,000. [link to online supplementary tables A1-2] Similar results were obtained when the 
sensitivity and specificity of case detection in current eye care were reduced to plausible minimum 
levels. [link to online supplementary tables B1-B2] 
 
Varying uptake of screening and current practice- Using alternative assumptions about the estimated 
uptake of current eye care services, varying from low annual uptake 6.5% (estimated uptake of eye 
care for low income households) to 17% (estimated uptake of eye care for people with diabetes) based 
upon BHPS data, and varying the assumed uptake of screening from 50-100%, the cost-effectiveness 
of screening improved, although the ICER remained well above a £30,000 threshold.  [link to online 
supplementary tables C1-2] 
Cost of sight impairment 
Figure 1 (a-c) shows the two-way sensitivity analyses results for the annual cost of sight impairment 
versus the percentage of screening uptake. That is, for each combination of cost of sight impairment 
and proportion of screening uptake, the figure shows the strategy with the highest net-benefit (e.g. 
willingness to pay times mean QALYs minus mean cost), assuming a £30,000 willingness to pay for a 
QALY.  
For the illustrated cohort (inception cohort aged 50, assumed 1% glaucoma prevalence and 17% 
annual uptake of current practice21) none of the screening pathways would have a higher net-benefit 
compared with current practice, unless the annual cost of sight impairment is above £19,000. When 
the annual cost of sight impairment is above £30,000 screening is worthwhile if the uptake of 
screening is above 30%, (Figure 1a). 
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Figure 1.   Strategies with the highest net-benefit (defined as £30,000 x mean QALYs minus mean costs) for 
alternative values of annual cost of sight impairment and percentage of screening uptake for a 50-year-old 
cohort.  Willingness to pay is £30,000.  
Figure 1.a) 1% Glaucoma prevalence and 17%21 uptake current eye care practice.  
 
 
For the range of values selected for the annual cost of sight impairment and uptake rate, only ‘current practice’, 
‘GPS11d (IOP + VF)’ or ‘GPS11 (IOP + VF)’ are potentially cost-effective when society is willing to pay 
£30,000 per QALY.  The dashed line is illustrative.   The screening strategy ‘GPS11d (IOP + VF)’ has the 
highest net-benefit when the screening uptake is 30% and the annual cost of sight impairment is £30,000.  The 
vertical continuous line at £19,000 cost of sight impairment illustrates that screening is not cost effective below 
this value, regardless of the screening uptake. 
 
For a higher risk sub-group (assumed glaucoma prevalence of 5%) a targeted screening programme 
(surveillance) could be worthwhile if the annual cost of sight impairment is above £3000, (Figure 1b).  
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Figure 1.b) 5% glaucoma prevalence and 17%22 uptake of current eye care.  
 
Note: The dashed line is illustrative. The screening strategy ‘GPS11d (IOP + VF)’ has the highest net-benefit for 
screening attendance of 40% and annual cost of sight impairment just above £4,500. The vertical continuous 
line at £3,000 cost of sight impairment illustrates that screening by any pathway is not cost effective below this 
value, regardless of screening uptake. 
 
Assuming a low uptake of current eye care (6.5% per year), as might be expected within a low income 
subgroup screening could be considered cost-effective if the annual cost of visual impairment is above 
£18,000 per year with screening uptake of 40% for a cohort with an assumed glaucoma prevalence of 
1%, (Figure 1c). 
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Figure 1.c) 1% glaucoma prevalence rate and 6.5%22 uptake of current eye care.  
 
Note: The dashed line is illustrative. The screening strategy GPS11d (IOP + VF)’ having the highest net-benefit 
for screening attendance of 40% and annual cost of sight impairment above £18,000. 
 
Enhancing current eye care - Increasing the uptake of current eye care for those in higher risk groups 
(>5% glaucoma prevalence), as opposed to a screening programme, is cost-effective when the annual 
cost of sight impairment is above £8000 and assuming no cost for a behavioural intervention to 
improve uptake.  Increasing uptake rates would, however, be likely to incur costs. The cost per 
individual of increasing uptake would need to be <£20 with an annual cost of sight impairment per 
person of £20,000 for this strategy to approach cost-effectiveness. Details results are available from 
the authors.  
The cost of sight impairment is uncertain. This uncertainty was built into the probabilistic sensitivity 
analysis by investigating the impact of the annual cost of visual impairment being equally likely to 
have any value between £1000 and £40,000 (i.e. assuming a uniform distribution) and investigating 
the value of removing all the imprecision around parameter estimates within the model i.e. the EVPI 
as well as the value of removing all uncertainty surrounding a particular (group of) parameter(s) i.e. 
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expected value of parameter perfect information (EVPPI). Figure 2 shows the average EVPI and 
EVPPI curves for a 50-year old cohort with a 5% prevalence rate of glaucoma (higher risk subgroup) 
and when uptake of current practice is 7.4% (described in Table 1). This situation was chosen as, 
based on the base case results, was the most likely scenario favouring screening. The value of 
removing the imprecision around the model parameter estimates is illustrated in Figure 2.  
Figure 2: Average Expected Value of Perfect Information (EVPI) and Expected Value of 
Parameter Perfect Information (EVPPI)* 
 
*Scenario: model start age (and screening) 50 years old, prevalence rate 5%, screening every 10 years, whole 
population, current practice annual eye test uptake rate 7.4%, average annual cost of sight impairment £20,500. 
The upper and lower bounds limits for this distribution were informed by the literature, 27,28 assuming that NHS 
treatment as well as PSS cost were included. Incremental Cost Effectiveness Ratio for moving to screening 
(GPS1d (IOP + VF) = £21,720). The peak in EVPI corresponds to the uncertainty in the decision of changing 
from current practice (opportunistic case finding) to screening with a technician conducting tonometry and 
visual field test (perimetry) with screen positives examined by a specialised optometrist (GPS11d (IOP + VF)). 
EVPPI shown for selected parameters that contributed the most to decision uncertainty.   
 
The peak in the EVPI curve corresponds to the willingness to pay for a QALY value where decision 
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uncertainty is at its highest (at around £20,000 WTP) and is the decision point on whether to screen or 
not. For a willingness to pay threshold of £20,000 for a QALY, the population EVPI is around £107 
million, with the costs of sight impairment contributing the most to this decision uncertainty (EVPPI, 
£74 million), followed by the uncertainty due to test performance (e.g. £14 million), and screening 
acceptance or current practice eye uptake rate (e.g. £8 million each).  
DISCUSSION 
We integrated new data on a feasible glaucoma-screening pathway, estimates of uptake of current eye 
care services, likely improvement of screening uptake by a behavioural intervention into an economic 
evaluation model of screening strategies for glaucoma, updating the original Glaucoma Screening 
Model. 5 Findings from the original evaluation suggested that glaucoma screening of a population 
selected on age is unlikely to be considered cost-effective at values for a QALY that society is 
typically willing to pay, but screening of high risk groups (prevalence of around 4%) might be. 
Glaucoma prevalence rises with age but in terms of life years to benefit from screening the optimal 
age for offering a screening programme is around age 50, however glaucoma prevalence for a 50-
year-old cohort is around 1%.5 In the revised GPS models we explored scenarios where screening 
might be worthwhile by varying screening uptake rate, performance and uptake of current practice.  
Across all the modelled scenarios the conclusion from the original evaluation is unchanged. Results 
were robust to all changes in the model parameter values except for the annual cost of sight 
impairment.  When taking a wider perspective on the costs of sight impairment, findings from the two 
way sensitivity analysis, varying screening uptake and costs of sight impairment, suggest that 
assuming higher estimated costs of sight impairment screening the general population selected on age 
alone as opposed to surveillance of high risk groups might be worthwhile.   
 
Data on the annual cost of sight impairment are very limited. The health costs of severe sight 
impairment due to glaucoma have been estimated as £800 per year (updated to 2010-2011 prices). 27 
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These costs do not include the personal and social care costs associated with sight impairment.  We 
accessed council data for England in an attempt to ascertain the annual personal and social cost of 
care for adults with sight impairment. For adults with physical disabilities, costs are estimated at 
£41,000 per year. These data did include estimates from people with sight loss but data were not 
reported separately. 24 The cost of sight impairment in the UK is reported by the Royal National 
Institute for the Blind as £12,457 per person per year.  28 However, these calculations include indirect 
costs (productivity losses), cost due to lower employment, premature mortality, as well as £8782 
corresponding to burden of disease cost – the use of such figures entails some double counting as 
some of these effects are captured within the QALY estimates. Estimates by Mead and Hyde suggest 
that the cost of blindness for another chronic eye condition, age related macular degeneration, range 
around £8,000  (updated to 2010-2011 prices) for the first year of blindness but highlighted the 
limitations in the data to determine the true costs of failing eyesight. 29   
The purpose of updating the original glaucoma screening model was to determine if, given the newly 
defined screening pathways and target population, a future large-scale glaucoma screening RCT 
would be value for money in terms of informing policy decisions on glaucoma screening in the UK.  
The value of removing all uncertainty in the model was around £107 million indicating that further 
research on glaucoma screening might be worthwhile.  The uncertainty around cost of sight 
impairment contributed most followed by the uncertainty around screening test performance, and the 
uptake of screening or current eye care services.  
These findings suggest that before proceeding to a large scale RCT evaluating  a glaucoma screening  
or surveillance programme, further research to understand and quantify the cost of sight impairment 
(NHS and Personal Social Services) is a priority.  These data would be best collected within a well-
designed cohort study, prospectively following individuals through the spectrum of visual impairment 
and as needs change and adaptation to sight loss occurs. 
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The effectiveness of any screening or surveillance programme requires that the target population 
attend. Our findings suggest that an evidence-informed behavioural intervention, such as a carefully 
worded invitation letter with a reminder or a more intensive intervention (eg tailored message, SMS 
reminder, buddy system) may improve attendance. 17 
Strengths and limitations  
This study used a transparent iterative approach building on a prior robust evidence synthesis and 
sought views of all stakeholders to inform decisions regarding glaucoma screening. We used robust 
qualitative and quantitative methods to provide an evidence-based recommendation for future 
research.  It was not within the scope of this study to estimate the accuracy of screening tests or to 
evaluate the accuracy of current eye care services in the detection of glaucoma. We used the same 
estimates of performance of community optometric detection of glaucoma (current eye care) as used 
in the original model, based on a survey conducted by Tuck and colleagues in the late 1980s 
evaluating outcomes from 300,000 sight tests in community optometry. This was the largest published 
study on community eye care but may not now represent contemporary practice.  To estimate 
screening test performance we used estimates from a prior evidence synthesis, but these were based 
on evidence from studies with heterogeneous populations and high risk of bias.   
We had limited data on the uptake of current eye care services by higher risk groups, particularly by 
ethnic minority groups and those who might expect to have a higher uptake of current eye care, those 
with a family history of glaucoma. We did however use new primary data from our survey on eye 
testing within the last few years and used data from the British Household Panel Survey that is 
considered to be representative panel data on uptake of health services in the UK.   
The value for information analysis can only capture those uncertainties incorporated into the 
economic model and is dependent on the model structure.  The model did not consider the potential 
harms due to screening (e.g. anxiety for those with false positives) or the side effects of treatment (e.g. 
cataracts).  While it is unlikely that these omissions would have a major impact on the model results, 
they are a limitation of the analysis. Finally, while the EVPI analysis constitutes a necessary condition 
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in determining whether further research is worthwhile it is not in itself sufficient to determine whether 
research should be conducted (although it can give a strong indication that further research is not 
worthwhile, if for example EVPI is less than the costs of conducting further research).  A positive 
Expected Net-benefit of Sampling (ENBS) constitutes a necessary and sufficient condition to conduct 
further research.  ENBS is the difference between the benefits of reducing uncertainty with a 
particular sample size study and the cost of obtaining that sample size.   Unfortunately, ENBS can be 
obtained only under very restrictive assumptions and is often computationally prohibitive and there 
have been few examples where it has been used in practice to inform, for example, the sample size of 
a trial.  30 In such circumstances we believe the EVPI establishes a first step to inform the judgment 
that further research is potentially worthwhile.  
CONCLUSIONS 
A glaucoma screening trial is currently unlikely to be the best use of research resources to inform 
policy decisions on screening policy in the UK.  Further research to quantify the health and personal 
social services costs of sight impairment is recommended.  Further development of glaucoma tests 
and an evaluation of a behavioural intervention to improve attendance for those who do not access 
current eye care services would be worthwhile. Our findings are UK specific, but the methods used 
and the modeling framework can be adapted and populated with country specific parameters. 
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